Latent Labs, a UK drug discovery startup launched by former Google DeepMind scientist Simon Kohl, has launched its first AI mannequin, with claims it may possibly outperform prime opponents.
AI drug discovery is rapidly changing into an intensively aggressive market, with dozens of startups pulling in tens of tens of millions – and within the case of DeepMind spinout Isomorphic Labs, a whole lot of tens of millions – in funding.
However the just lately launched Latent Labs, which closed a $50m (£37m) Sequence A spherical in February, claims to be forward of the curve with the launch its frontier AI mannequin Latent-X.
Obtainable for early entry, Latent-X is an AI mannequin for push button protein design with which customers can add protein targets and generate cyclic peptides and mini-binders straight within the browsers.
Releasing a working mannequin is an achievement in itself, nevertheless, the corporate has made daring claims about its efficiency, suggesting that in head-to-head testing, it outperforms the mannequin developed by Isomorphic Labs, the work of which earned its founder Sir Demis Hassabis a Nobel Prize.
“We envision a future the place efficient therapeutics could be designed completely in a pc, like semiconductors or area missions,” stated Kohl.
“Our platform empowers scientists with lab-validated protein binder design at their fingertips, whether or not they’re consultants or new to AI-powered drug design, and without having AI infrastructure. This is step one on our mission towards making biology programmable in an effort to make drug design instantaneous.”
Latent Labs stated its mannequin generates designs over 10 instances sooner than earlier strategies. Latent-X could be accessed by industrial and non-commercial customers through a free and premium tier.
Register for Free
Bookmark your favourite posts, get every day updates, and revel in an ad-reduced expertise.
Have already got an account? Log in
